D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

That's from Vanda Research's new bulletin analyzing the trading of non-institutional stock market players. Vanda observes that between Friday and Tuesday’s close, "mom-and-pop traders" poured ...

according to data released by Vanda Research on Wednesday. Retail investors poured one out of every three dollars of their investments into Nvidia shares in the first days of this week when the AI ...

(Reuters) - Individual investors responded to the market selloff earlier this week triggered by concerns regarding a Chinese artificial intelligence startup by buying a wide array of technology stocks ...

H.C. Wainwright maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ:VNDA) with a price target of $18.00, representing significant upside potential from the current price of $4.31. According to ...